This Page Score: 0/40
Match the terms in List-I related to ethical and traditional knowledge with their definitions in List-II:
| List-I (Term) | List-II (Definition/Area) |
|---|---|
| A. GEAC | P. Organisation evaluating validity/safety of GM research |
| B. Biopiracy | Q. Use of bio-resources without authorization/compensatory payment |
| C. Traditional knowledge | R. Rich in developing and underdeveloped world |
| D. Basmati Rice (Indian varieties) | S. Used to create a 'new' variety claimed by an American company |
[Biotechnology-and-its-Applications] [class-xii ]
Match the insulin-related entities in List-I with their specific characteristics in List-II:
| List-I (Insulin Entity) | List-II (Characteristic) |
|---|---|
| A. Pro-hormone | P. Contains an extra stretch called C peptide |
| B. Mature Insulin | Q. Two polypeptide chains (A and B) linked by disulphide bridges |
| C. Insulin from slaughtered animals | R. Risk of causing allergy or immune reactions |
| D. Eli Lilly (1983) | S. First to produce insulin chains separately using E. coli plasmids |
[Biotechnology-and-its-Applications] [class-xii ]
Match the gene therapy concepts in List-I with their descriptions in List-II:
| List-I (Gene Therapy Concept) | List-II (Description/Method) |
|---|---|
| A. Gene Therapy | P. Correction of a gene defect diagnosed in a child/embryo |
| B. First Clinical Gene Therapy | Q. Given in 1990 for ADA deficiency |
| C. Permanent Cure Goal | R. Introduction of the functional gene at early embryonic stages |
| D. Retroviral Vector | S. Used to introduce functional ADA cDNA into lymphocytes |
[Biotechnology-and-its-Applications] [class-xii ]
Match the diagnostic tools/methods in List-I with their principles in List-II:
| List-I (Tool/Method) | List-II (Principle/Mechanism) |
|---|---|
| A. PCR | P. Amplification of nucleic acid to detect low concentrations of pathogens |
| B. ELISA | Q. Based on antigen-antibody interaction |
| C. Radioactive Probe | R. Tags single-stranded DNA/RNA to hybridise to complementary sequence |
| D. Conventional Diagnosis | S. Early detection is not possible |
[Biotechnology-and-its-Applications] [class-xii ]
Match the features of Transgenic Animals in List-I with their details in List-II:
| List-I (Transgenic Feature) | List-II (Detail/Usage) |
|---|---|
| A. Most common transgenic animal | P. Mice (over 95 per cent of all existing transgenic animals) |
| B. Normal Physiology Study | Q. Used to study insulin-like growth factor |
| C. Vaccine Safety Testing | R. Used to test safety of polio vaccine |
| D. Biological Product example | S. Human α-1-antitrypsin to treat emphysema |
[Biotechnology-and-its-Applications] [class-xii ]
Match the disease models in List-I with their corresponding transgenic animal applications in List-II:
| List-I (Disease) | List-II (Transgenic Role) |
|---|---|
| A. Cancer | P. Model to understand how genes contribute to development |
| B. Alzheimer’s | Q. Model exists for investigation of new treatments |
| C. Cystic Fibrosis | R. Transgenic animal models exist |
| D. Rheumatoid Arthritis | S. Transgenic models exist to investigate treatments |
[Biotechnology-and-its-Applications] [class-xii ]
Match the ethical/legal terms in List-I with their related descriptions in List-II:
| List-I (Legal/Ethical Term) | List-II (Description/Concern) |
|---|---|
| A. Genetic Modification Ethics | P. Can have unpredictable results when introduced into ecosystem |
| B. Indian Parliament Action | Q. Recently cleared the second amendment of the Indian Patents Bill |
| C. Industrially Rich Nations | R. Rich financially but poor in biodiversity and traditional knowledge |
| D. Basmati Patent Restriction | S. Patent extended to functional equivalents, restricting sellers |
[Biotechnology-and-its-Applications] [class-xii ]
Match the plant tissue culture applications in List-I with their outcome/purpose in List-II:
| List-I (Application) | List-II (Outcome/Purpose) |
|---|---|
| A. Micro-propagation | P. Producing thousands of plants in short durations |
| B. Meristem Culture | Q. Recovery of healthy plants from diseased plants |
| C. Protoplast Isolation | R. Done by digesting cell walls of single cells |
| D. Somaclones | S. Genetically identical to the original plant |
[Biotechnology-and-its-Applications] [class-xii ]
Match the components of the RNAi mechanism in List-I with their functions in List-II:
| List-I (Component/Organism) | List-II (Role/Feature) |
|---|---|
| A. RNA interference (RNAi) | P. Method of cellular defense in all eukaryotic organisms |
| B. *Meloidegyne incognitia* | Q. Nematode that infects tobacco roots |
| C. dsRNA | R. Initiates RNAi, silencing specific mRNA |
| D. Agrobacterium vectors | S. Used to introduce nematode-specific genes into host plant |
[Biotechnology-and-its-Applications] [class-xii ]
Match the diagnostic methods in List-I with the level of pathogen concentration they can detect in List-II:
| List-I (Method) | List-II (Detection Feature) |
|---|---|
| A. PCR | P. Can detect very low concentration of viruses/bacteria |
| B. ELISA | Q. Detects presence of antigens or antibodies synthesized |
| C. Conventional Diagnosis (Serum/Urine) | R. Pathogen concentration is already very high when symptoms appear |
| D. Molecular Diagnosis | S. Serves the purpose of early diagnosis |
[Biotechnology-and-its-Applications] [class-xii ]
This Page Score: 0/40